Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer
2020
Triple-negative breast cancer (TNBC) is the most aggressive type of cancer, with a high risk of death on recurrence. To date, there is a lack of approved targeted agents for the treatment of the disease. Patients with TNBC continue to depend on surgery, chemotherapy, and radiotherapy, all of which have a wide side effect profile. In the present review, we highlight the current progress and exciting developments in the small-molecule targeted therapy for the treatment of TNBC. Finally, we also discuss the prospect of combining targeted therapy and immunotherapy for the effective treatment of TNBC.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
184
References
13
Citations
NaN
KQI